Insider tradingForm 4
Amylyx Pharmaceuticals, Inc. (AMLX) Insider Trading
6 open-market trades reported since Sep 14, 2026: 0 purchases worth $0 and 6 sales worth $3.78M.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| George M. Milne Jr | Director | 0 | $0 | 1 | $831K |
| Joshua B. Cohen | CEO | 0 | $0 | 1 | $981K |
| Justin B. Klee | CEO | 0 | $0 | 1 | $980K |
| James M. Frates | CFO | 0 | $0 | 1 | $350K |
| Camille L. Bedrosian | Chief Medical Officer | 0 | $0 | 1 | $325K |
| Gina Mazzariello | General Counsel | 0 | $0 | 1 | $310K |
All trades
| Filed | Insider | Type | Value | 3 mo. after |
|---|---|---|---|---|
| Oct 7 | George M. Milne JrDirector | ▼ SELL10b5-1 | $831K | |
| Sep 14 | Joshua B. CohenCEO | ▼ SELL | $981K | |
| Sep 14 | Justin B. KleeCEO | ▼ SELL | $980K | |
| Sep 14 | James M. FratesCFO | ▼ SELL | $350K | |
| Sep 14 | Camille L. BedrosianChief Medical Officer | ▼ SELL | $325K | |
| Sep 14 | Gina MazzarielloGeneral Counsel | ▼ SELL | $310K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings